|
ES2566056T3
(es)
*
|
2001-03-29 |
2016-04-08 |
Eli Lilly And Company |
N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
|
|
MXPA04001089A
(es)
*
|
2001-08-03 |
2004-05-20 |
Upjohn Co |
5-arilsulfonil indoles que tienen afinidad por el receptor de 5-ht.
|
|
ES2297216T3
(es)
|
2002-06-21 |
2008-05-01 |
Suven Life Sciences Limited |
Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina.
|
|
KR100645412B1
(ko)
*
|
2002-07-17 |
2006-11-15 |
레크 파마슈티칼스 디.디. |
콜레스테롤 생합성 억제제로서의 신규한 피리딜에탄올(페닐에틸)아민 유도체, 그의 제조 방법 및 그를 함유하는제약 조성물
|
|
PT2208727E
(pt)
|
2002-09-19 |
2012-10-11 |
Lilly Co Eli |
Éteres diarílicos como antagonista do receptor opióide
|
|
CA2508290C
(en)
*
|
2002-12-20 |
2017-02-28 |
Ciba Specialty Chemicals Holding Inc. |
Synthesis of amines and intermediates for the synthesis thereof
|
|
WO2004080968A1
(en)
|
2003-03-07 |
2004-09-23 |
Eli Lilly And Company |
6-substituted nicotinamide derivatives as opioid receptor antagonists
|
|
EP1606275B1
(en)
|
2003-03-07 |
2008-08-27 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
DE10320782A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
NZ544331A
(en)
|
2003-07-22 |
2010-03-26 |
Arena Pharm Inc |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
|
BRPI0417714A
(pt)
|
2003-12-22 |
2007-03-20 |
Lilly Co Eli |
composto, composição farmacêutica, e, uso de um composto
|
|
US7381750B2
(en)
|
2004-03-12 |
2008-06-03 |
Eli Lilly And Company |
Amino-phenoxymethyl-benzamide opioid receptor antagonists
|
|
WO2005090303A1
(en)
|
2004-03-15 |
2005-09-29 |
Eli Lilly And Company |
4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
|
|
US7378448B2
(en)
|
2004-03-15 |
2008-05-27 |
Eli Lilly And Company |
Diphenylether amide derivatives as opioid receptor antagonists
|
|
CA2881078C
(en)
*
|
2004-06-24 |
2018-10-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
EP1632491A1
(en)
*
|
2004-08-30 |
2006-03-08 |
Laboratorios Del Dr. Esteve, S.A. |
Substituted indole compounds and their use as 5-HT6 receptor modulators
|
|
MX2007003375A
(es)
|
2004-09-22 |
2007-05-07 |
Janssen Pharmaceutica Nv |
Inhibidores de la interaccion entre mdm2 y p53.
|
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
|
DE102004062542A1
(de)
*
|
2004-12-24 |
2006-07-06 |
Bayer Cropscience Ag |
Substituierte Oxyarene
|
|
LT1993360T
(lt)
|
2005-12-28 |
2017-06-12 |
Vertex Pharmaceuticals Incorporated |
N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
|
|
CN101351707B
(zh)
*
|
2005-12-28 |
2014-03-26 |
积水医疗株式会社 |
凝集测量用试剂以及凝集测量方法
|
|
EP1973905A4
(en)
*
|
2006-01-06 |
2010-12-08 |
Astrazeneca Ab |
COMPOUNDS
|
|
WO2007107543A1
(en)
*
|
2006-03-22 |
2007-09-27 |
Janssen Pharmaceutica N.V. |
Inhibitors of the interaction between mdm2 and p53
|
|
AU2007228784B2
(en)
|
2006-03-22 |
2012-03-08 |
Janssen Pharmaceutica N.V. |
Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
|
|
TWI389889B
(zh)
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
|
|
EP2021325A2
(en)
|
2006-05-09 |
2009-02-11 |
AstraZeneca AB |
Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
|
|
EP1953153A1
(en)
*
|
2007-01-31 |
2008-08-06 |
Laboratorios del Dr. Esteve S.A. |
Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
|
|
AR067813A1
(es)
|
2007-08-06 |
2009-10-21 |
Janssen Pharmaceutica Nv |
Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
|
|
JO2704B1
(en)
*
|
2007-09-21 |
2013-03-03 |
جانسين فارماسوتيكا ان في |
Interference inhibition factors between MD2 and B53
|
|
EP2209380A4
(en)
*
|
2007-10-09 |
2011-09-14 |
Mark T Hamann |
METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
|
|
JP2011505418A
(ja)
*
|
2007-12-04 |
2011-02-24 |
メルク・シャープ・エンド・ドーム・コーポレイション |
５−ｈｔ６アンタゴニストとしてのトリプタミンスルホンアミド
|
|
EP2254564A1
(en)
|
2007-12-12 |
2010-12-01 |
Glaxo Group Limited |
Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
|
|
US20090318527A1
(en)
*
|
2008-02-11 |
2009-12-24 |
Howard Sard |
Indole compounds and methods of use thereof
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
|
EA021883B1
(ru)
|
2009-02-04 |
2015-09-30 |
Янссен Фармацевтика Нв |
Производные индола в качестве противораковых агентов
|
|
JP5083256B2
(ja)
*
|
2009-03-20 |
2012-11-28 |
株式会社デンソー |
半導体装置およびその製造方法
|
|
SI3330255T1
(sl)
|
2009-03-20 |
2021-03-31 |
Vertex Pharmaceuticals Incorporated |
Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
|
|
US8912220B2
(en)
|
2009-08-10 |
2014-12-16 |
Galenea Pharmaceuticals |
Compounds and methods of use thereof
|
|
EP2311823A1
(en)
|
2009-10-15 |
2011-04-20 |
AC Immune S.A. |
2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
|
|
TW201139370A
(en)
|
2009-12-23 |
2011-11-16 |
Lundbeck & Co As H |
Processes for the manufacture of a pharmaceutically active agent
|
|
FR2961095B1
(fr)
*
|
2010-06-09 |
2012-06-15 |
Oreal |
Composition cosmetique et/ou dermatologique comprenant au moins un compose 6-alcoxy tryptamine
|
|
FR2961097B1
(fr)
*
|
2010-06-09 |
2012-07-13 |
Oreal |
Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 6-alkoxy tryptamine
|
|
US8293218B2
(en)
*
|
2010-07-29 |
2012-10-23 |
Conopco, Inc. |
Skin care compositions comprising substituted monoamines
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
WO2014165701A1
(en)
*
|
2013-04-03 |
2014-10-09 |
The University Of Utah Research Foundation |
Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
|
|
EP2819670B1
(en)
|
2012-02-27 |
2026-05-20 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical Composition and Their Administration
|
|
KR20140135835A
(ko)
*
|
2012-03-20 |
2014-11-26 |
아다메드 에스피. 제트 오.오. |
Cns 질환의 치료를 위한 벤질아민의 설폰아미드 유도체
|
|
CN102746211B
(zh)
*
|
2012-06-27 |
2015-05-27 |
上海泰坦化学有限公司 |
一种取代吲哚-3-甲醛类化合物的制备方法
|
|
JO3459B1
(ar)
*
|
2012-09-09 |
2020-07-05 |
H Lundbeck As |
تركيبات صيدلانية لعلاج مرض الزهايمر
|
|
US10154988B2
(en)
|
2012-11-14 |
2018-12-18 |
The Johns Hopkins University |
Methods and compositions for treating schizophrenia
|
|
CN104725249B
(zh)
*
|
2013-12-20 |
2019-02-12 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
JO3639B1
(ar)
*
|
2014-07-04 |
2020-08-27 |
H Lundbeck As |
صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
|
|
CA2963945C
(en)
|
2014-10-07 |
2023-01-10 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
|
ES2570452B1
(es)
*
|
2014-10-15 |
2017-04-19 |
Fundación Para La Investigación Biomédida Del Hospital Universitario De La Princesa |
Compuestos derivados de acrilato de 3-Alquilamino-1H-Indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
|
|
CN105175307A
(zh)
*
|
2014-11-18 |
2015-12-23 |
苏州晶云药物科技有限公司 |
Lu AE58054的盐酸盐晶型A及其制备方法和用途
|
|
CN104529865B
(zh)
*
|
2014-12-12 |
2017-02-01 |
广东东阳光药业有限公司 |
苄胺类衍生物及其在药物上的应用
|
|
TW201630881A
(zh)
|
2014-12-12 |
2016-09-01 |
Ｈ 朗德貝克公司 |
用於生產艾達魯吡啶之方法
|
|
JP2018516992A
(ja)
|
2015-06-12 |
2018-06-28 |
アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ |
レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
|
|
CN108472285A
(zh)
|
2015-07-15 |
2018-08-31 |
阿速万科学有限责任公司 |
用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
|
|
CN108271369A
(zh)
|
2015-10-23 |
2018-07-10 |
法尔玛赞公司 |
用于制备色胺及其衍生物的新工艺
|
|
EP3440055B1
(en)
*
|
2016-04-08 |
2020-03-11 |
H. Lundbeck A/S |
A process for the manufacture of idalopirdine via hydrogenation of an imine
|
|
KR102473545B1
(ko)
|
2016-04-26 |
2022-12-01 |
하. 룬드벡 아크티에셀스카브 |
파킨슨병 환자에서 낙상을 감소시키기 위한 아세틸콜린에스테라아제 억제제 및 아이달로피르딘의 용도
|
|
US10864191B2
(en)
|
2016-05-11 |
2020-12-15 |
H. Lundbeck A/S |
5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
|
|
WO2018013686A1
(en)
*
|
2016-07-12 |
2018-01-18 |
Concert Pharmaceuticals, Inc. |
Deuterated idalopirdine
|
|
EP3333154A1
(en)
|
2016-12-07 |
2018-06-13 |
Sandoz Ag |
Crystalline form of a selective 5-ht6 receptor antagonist
|
|
CN106632303A
(zh)
*
|
2017-01-09 |
2017-05-10 |
湖南华腾制药有限公司 |
一种6‑噻唑基吲哚衍生物的制备方法
|
|
WO2018191146A1
(en)
*
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
RS61704B1
(sr)
|
2017-05-24 |
2021-05-31 |
H Lundbeck As |
Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
|
|
CA3079819C
(en)
*
|
2017-11-06 |
2023-03-14 |
Acelot, Inc. |
Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
|
|
US12240855B2
(en)
|
2019-03-06 |
2025-03-04 |
Daiichi Sankyo Company, Limited |
Pyrrolopyrazole derivative
|
|
CN109942527A
(zh)
*
|
2019-04-26 |
2019-06-28 |
新乡市润宇新材料科技有限公司 |
一种3-溴二苯并呋喃的合成方法
|
|
IL297861A
(en)
|
2020-05-08 |
2023-01-01 |
Psilera Inc |
Novel compositions of matter and pharmaceutical compositions
|
|
IL312785B2
(en)
|
2020-05-19 |
2026-06-01 |
Cybin Irl Ltd |
Deuterated tryptamine derivatives and methods of use
|
|
JP2023539390A
(ja)
*
|
2020-09-02 |
2023-09-13 |
エンベリック バイオサイエンシズ カナダ インコーポレイテッド |
ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用
|
|
US12559491B2
(en)
*
|
2020-09-17 |
2026-02-24 |
Merck Sharp & Dohme Llc |
Modified imidazopyridines as glucosylceramide synthase inhibitors
|
|
MX2023009491A
(es)
*
|
2021-02-12 |
2023-10-13 |
Enveric Biosciences Canada Inc |
Derivados de psilocibina de múltiples sustituyentes y métodos de uso.
|
|
MX2023010317A
(es)
*
|
2021-03-02 |
2023-11-09 |
Mindset Pharma Inc |
Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
|
|
CA3217737A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Jason WALLACH |
Selective, partial, and arrestin-biased 5-ht2a agonists with utility in various disorders
|
|
KR20240013170A
(ko)
|
2021-05-25 |
2024-01-30 |
아타이 테라퓨틱스, 인크. |
신규 n,n-디메틸트립타민 염 및 결정질 염 형태
|
|
JP2024520832A
(ja)
*
|
2021-06-08 |
2024-05-24 |
エンセオジェニックス バイオサイエンシズ， インコーポレイテッド |
セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
|
|
IL309210A
(en)
|
2021-06-09 |
2024-02-01 |
Atai Therapeutics Inc |
Parent drugs and conjugates of dimethyltryptamine
|
|
WO2023044577A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Psygen Inc. |
Recovery method for tryptamines
|
|
KR20240093980A
(ko)
*
|
2021-10-29 |
2024-06-24 |
리유니온 뉴로사이언스 인코포레이티드 |
신규한 벤질트립타민 화합물
|
|
CA3242479A1
(en)
|
2021-12-27 |
2023-07-06 |
Atai Therapeutics, Inc. |
AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
|
|
CA3238440A1
(en)
|
2021-12-30 |
2023-07-06 |
Atai Therapeutics, Inc. |
Dimethyltryptamine analogues as nitric oxide delivery drugs
|
|
US12065404B2
(en)
|
2022-03-18 |
2024-08-20 |
Enveric Biosciences Canada Inc. |
C4-carboxylic acid-substituted tryptamine derivatives and methods of using
|
|
US12343319B2
(en)
|
2023-05-01 |
2025-07-01 |
Atai Therapeutics, Inc. |
Compositions and methods for treatment of diseases and disorders
|
|
US20250243160A1
(en)
*
|
2024-01-24 |
2025-07-31 |
Automera PTE. LTD |
Indole derivatives for targeting autophagy
|
|
CN122233971A
(zh)
*
|
2026-05-25 |
2026-06-19 |
安徽泽升科技股份有限公司 |
一种6-取代吲哚的高效合成方法
|